Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. - Wikidata - wikimedia - TriplyDB

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

http://www.wikidata.org/entity/Q34447846

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells Radioresistance of Brain Tumors A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy Specific blockade of Rictor-mTOR association inhibits mTORC2 activity and is cytotoxic in glioblastoma.Thymoquinone-induced platelet apoptosis.Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells Glial progenitors as targets for transformation in glioma.A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy.Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets.The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.Current trends in targeted therapies for glioblastoma multiforme Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors Novel therapeutic targets in the brain tumor microenvironment Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway.MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.Mechanistic Target of Rapamycin (mTOR) Inhibition Synergizes with Reduced Internal Ribosome Entry Site (IRES)-mediated Translation of Cyclin D1 and c-MYC mRNAs to Treat Glioblastoma.Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.Overexpression of TELO2 decreases survival in human high-grade gliomas.PKC signaling in glioblastoma.Epidermal growth factor receptor as a therapeutic target in glioblastoma.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer.MSK1-Mediated β-Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma.The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction Aplysin induces apoptosis in glioma cells through HSP90/AKT pathway Radiosensitization of Glioblastoma Cell Lines by the Dual PI3K and mTOR Inhibitor NVP-BEZ235 Depends on Drug-Irradiation Schedule.Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.PI3K-AKT signaling is a downstream effector of retinoid prevention of murine basal cell carcinogenesis.Abundance of Flt3 and its ligand in astrocytic tumors Structure of the Toll/Interleukin-1 Receptor (TIR) Domain of the B-cell Adaptor That Links Phosphoinositide Metabolism with the Negative Regulation of the Toll-like Receptor (TLR) Signalosome.The effects of PI3K-mediated signalling on glioblastoma cell behaviour.Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.Interference of P-REX2a may inhibit proliferation and reverse the resistance of SGC7901 cells to doxorubicin.Optogenetically controlled protein kinases for regulation of cellular signaling.Phosphorylated 4E-binding protein 1 (p-4E-BP1): a novel prognostic marker in human astrocytomas.

P2860

Q21133610-095EF631-7255-4BF4-ADFF-96B646DEE397 Q24293124-6B196CE5-31E9-418F-A11B-412AA20F24BD Q26752579-12F5A843-779E-48A8-B53B-702F132FF079 Q26849503-F3FA49A0-81D4-4F36-B131-1B2CD6AE49C7 Q33615797-ECEE8002-E763-4590-9A5B-9CB801DB3096 Q34193945-56D1D935-D67F-4290-8DB7-E4107B728707 Q34455213-3B6ACF98-1BC8-48D5-A823-FE817B1267BC Q34735661-6A0FE059-6E32-4253-BC64-7A5CF903D709 Q35677134-0208A9D2-BE62-409B-A0BD-5541DA1054CC Q35748107-14BB27FF-B9FA-4183-AD01-C6D82FA5250C Q35864082-59F5B0F3-F59D-4D44-97B0-F6A7E149A018 Q35864226-6FE29D8D-64EA-4DA9-B134-209E69A8A235 Q35976820-0DDCBC89-B1C4-4220-A3E7-BED19A4456F9 Q36071884-BEF2F986-D11A-4D4F-AE8A-3F953A9A8F05 Q36214062-B77F408F-85F6-49C1-AE6A-56D3C550AAEA Q36278102-469AE80E-CEDA-49F9-89D0-EEA5F366F1A0 Q36315289-5B14444A-6C0A-436F-9FF0-DF86724B618C Q37065737-C5605183-2AAD-44A0-8931-7633ACE60486 Q37154148-8F8796F6-E11B-40EB-A04E-B17C3651CD57 Q37564650-7B8CD2AB-1167-4C98-BCD1-9E846D6315F8 Q38077454-5726E3BC-1ED3-4E96-AD31-657ACFD3C159 Q38098098-3DB61C54-B5D5-4F15-A986-235621DD99D6 Q38203283-EA804C82-8D01-48D4-A611-A96555E9978B Q38218129-EFF481D0-9EA0-4E70-847F-05135EE6EB57 Q38769933-F6B479E3-2FC1-42FD-A010-387CC3676E9C Q38772498-B3CF93D3-4339-4757-82FF-9ED84A106C5B Q38825141-DC7AA369-F9C9-4503-A406-F24F04D3E7C1 Q38838030-B5FB89FC-4C07-4618-8B92-4936788B8AF5 Q38892371-0D6025CA-760A-4A81-8211-28018AE922C8 Q38942128-C4525E4D-D875-4332-B975-4B3F1E0209D5 Q39382265-0695BAB2-9CED-4133-8469-48F4778E0072 Q39421577-9CB788B5-C4C2-4331-8A3D-2C7BE36C2C26 Q40355706-06B4DA6B-8CAA-4A66-A2F3-C9F1EFF1E962 Q41226132-7EF7ED59-45D1-41FB-9046-FBDCD09257A8 Q41860966-94E6F701-1E0C-4F52-8206-43DB06E999FA Q47945880-9A7CE3C7-86FB-4255-8EB9-1B0B8BFF85BE Q49407554-E78C9427-A25F-449E-B5E1-F307C6E9DFFA Q49703984-3E360562-B004-4B01-AAB4-0BCF62862E7D Q50421174-5E80160F-5605-4AAF-8FF1-61F2C6BCCE89 Q54504827-97530AA5-8055-4602-BCDD-D34E809A090B

P2860

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

http://www.wikidata.org/entity/Q34447846

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@ast

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@en

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@nl

type

label

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@ast

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@en

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@nl

prefLabel

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@ast

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@en

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@nl

P1433

Q34447846-5F770950-E2CA-463C-8105-20497580069C

P1476

Q34447846-440214C9-7412-4477-8ABE-CDEB1F9C7542

P2093

Q34447846-7D119ED0-7AF6-4730-9290-63819F487E9D

Q34447846-D1CD43B8-FDEC-40BD-87AA-054ECED8856E

P2860

Q34447846-03EDF372-594C-4BAC-A5BE-4F5908A2F2F6

Q34447846-0EF31F26-274B-447E-8341-CEC9454ACDA8

Q34447846-0FABB362-55DA-488A-9A88-2F9C6307A4CB

Q34447846-112910EB-22A8-4B95-BF44-6DE73479907D

Q34447846-11978096-80C0-4BF4-A133-622DB9F66251

Q34447846-172BD448-2BC9-4E9D-BB49-BE51EA824234

Q34447846-1AE3721C-529F-47D6-9524-9566A1544681

Q34447846-23F8A22B-9527-4AD7-B150-B05784D8FD50

Q34447846-273A07FD-21B7-42C8-A049-61EB8B978E01

Q34447846-398B2493-4045-4A6E-BAE9-2B51CACB753D

P304

Q34447846-75246607-639E-459C-B608-13D800C432E6

P31

Q34447846-4FF0F5FC-5EE4-4035-8E3F-299CAE358D5B

P356

Q34447846-43C0CB64-5F8A-4485-9CB3-48D21FC3A5EA

P478

Q34447846-A333AD0C-0563-4961-ADF7-B4AC7596EFC1

P577

Q34447846-A3C3D874-1CFC-4E97-BF33-2DEBDED35E77

P5875

Q34447846-8C8FC876-5A1A-44DB-83F4-96FA1CE79B5B

P698

Q34447846-CB39B80A-65B7-4D5C-B90C-4BFE5E80CFA7

P932

Q34447846-303BCE48-E332-4E30-AD4D-171CF0567470

P356

P1433

Current Topics in Microbiology and Immunology

P1476

Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

@en

P2093

Qi-Wen Fan

http://www.w3.org/2001/XMLSchema#string

William A Weiss

http://www.w3.org/2001/XMLSchema#string

P2860

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

AKT/PKB signaling: navigating downstream

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

PI 3-kinase p110beta: a new target for antithrombotic therapy

P304

279-296

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/82_2010_67

http://www.w3.org/2001/XMLSchema#string

P478

347

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44661225

http://www.w3.org/2001/XMLSchema#string

P698

20535652

http://www.w3.org/2001/XMLSchema#string

P932

3012004

http://www.w3.org/2001/XMLSchema#string